WEDNESDAY, May 10, 2023 (HealthDay News) Researchers have isolated for the first time a free-floating form of amyloid beta that appears to be a key driver of Alzheimer’s disease.
Patients with early, symptomatic Alzheimer s disease had significantly better amyloid clearance and plaque reduction after 6 months of treatment with donanemab compared with aducanumab.